Financials data is unavailable for this security.
View more
Year on year Beijing Foyou Pharma Co Ltd grew revenues 3.07% from 3.24bn to 3.34bn while net income improved 11.36% from 438.90m to 488.77m.
| Gross margin | 65.53% |
|---|---|
| Net profit margin | 14.99% |
| Operating margin | 16.09% |
| Return on assets | 11.43% |
|---|---|
| Return on equity | 14.97% |
| Return on investment | 14.76% |
More ▼
Cash flow in CNYView more
In 2023, Beijing Foyou Pharma Co Ltd did not generate a significant amount of cash. However, the company earned 555.90m from its operations for a Cash Flow Margin of 16.65%. In addition the company used 385.66m on investing activities and also paid 206.68m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 7.39 |
|---|---|
| Tangible book value per share | 7.08 |
More ▼
Balance sheet in CNYView more
| Current ratio | 3.06 |
|---|---|
| Quick ratio | 2.73 |
| Total debt/total equity | 0.0252 |
|---|---|
| Total debt/total capital | 0.0245 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 25.00% and 11.36%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 46.08% |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 4.53 |
More ▼
